{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:05:49Z","timestamp":1794679549882,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12883-017-0836-z","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T11:57:52Z","timestamp":1492775872000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study"],"prefix":"10.1186","volume":"17","author":[{"given":"Colette","family":"Mankowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris D.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Ernault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Berni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig J.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecil","family":"Treadwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 I.","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Plastira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Zafeiropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Odeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"issue":"18","key":"836_CR1","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","volume":"70","author":"RD Treede","year":"2008","unstructured":"Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630\u20135.","journal-title":"Neurology"},{"issue":"3","key":"836_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2174\/157015906778019536","volume":"4","author":"P Marchettini","year":"2006","unstructured":"Marchettini P, Lacerenza M, Mauri E, Marangoni C. Painful peripheral neuropathies. Curr Neuropharmacol. 2006;4(3):175\u201381.","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"836_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jpain.2005.11.008","volume":"7","author":"N Torrance","year":"2006","unstructured":"Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7(4):281\u20139.","journal-title":"J Pain"},{"issue":"3","key":"836_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","volume":"136","author":"D Bouhassira","year":"2008","unstructured":"Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380\u20137.","journal-title":"Pain"},{"issue":"2","key":"836_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.pain.2010.02.034","volume":"149","author":"AH Doth","year":"2010","unstructured":"Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain. 2010;149(2):338\u201344.","journal-title":"Pain"},{"issue":"2","key":"836_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162\u201373.","journal-title":"Lancet Neurol"},{"key":"836_CR7","doi-asserted-by":"publisher","unstructured":"Haanp\u00e4\u00e4 M, Treede RD. Neuropathic Pain. In Lynch ME, Craig KD & Peng PWH (eds). Clinical pain management: a practical guide. Oxford: Wiley-Blackwell; 2010: 281-9.","DOI":"10.1002\/9781444329711.ch34"},{"issue":"3","key":"836_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11916-007-0192-6","volume":"11","author":"JM Wallace","year":"2007","unstructured":"Wallace JM. Update on pharmacotherapy guidelines for treatment of neuropathic pain. Curr Pain Headache Rep. 2007;11(3):208\u201314.","journal-title":"Curr Pain Headache Rep"},{"issue":"6","key":"836_CR9","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00228-012-1464-6","volume":"69","author":"M Gahr","year":"2013","unstructured":"Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69(6):1335\u201342.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"836_CR10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/bja\/aer260","volume":"107","author":"P Anand","year":"2011","unstructured":"Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490\u2013502.","journal-title":"Br J Anaesth"},{"issue":"2","key":"836_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40122-014-0027-1","volume":"3","author":"N Uceyler","year":"2014","unstructured":"Uceyler N, Sommer C. High-dose capsaicin for the treatment of neuropathic pain: what we know and what we need to know. Pain Ther. 2014;3(2):73\u201384.","journal-title":"Pain Ther"},{"issue":"12","key":"836_CR12","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(08)70228-X","volume":"7","author":"M Backonja","year":"2008","unstructured":"Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan Jr P, Rauck R, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7(12):1106\u201312.","journal-title":"Lancet Neurol"},{"issue":"2","key":"836_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/QAI.0b013e31823e31f7","volume":"59","author":"DB Clifford","year":"2012","unstructured":"Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ, Conway B, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr. 2012;59(2):126\u201333.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"836_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1526-4637.2010.01004.x","volume":"12","author":"GA Irving","year":"2011","unstructured":"Irving GA, Backonja MM, Dunteman E, Blonsky ER, Vanhove GF, Lu SP, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12(1):99\u2013109.","journal-title":"Pain Med"},{"issue":"6","key":"836_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1185\/03007995.2013.792246","volume":"29","author":"C Maihofner","year":"2013","unstructured":"Maihofner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12\u00a0weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin. 2013;29(6):673\u201383.","journal-title":"Curr Med Res Opin"},{"key":"836_CR16","doi-asserted-by":"publisher","unstructured":"Simpson DM, Brown S, Tobias J, the NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305\u201313.","DOI":"10.1212\/01.wnl.0000314647.35825.9c"},{"key":"836_CR17","unstructured":"Stoker M, Katz N, Van J, Snijder R, Jacobs H, Long S, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomised, double-blind, placebo-controlled study. Diabetologia. 2015;58(Suppl. 1):S32."},{"issue":"2","key":"836_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ejp.731","volume":"20","author":"M Haanp\u00e4\u00e4","year":"2016","unstructured":"Haanp\u00e4\u00e4 M, Cruccu G, Nurmikko TJ, McBride WT, Docu Axelarad A, Bosilkov A, et al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur J Pain. 2016;20(2):316\u201328.","journal-title":"Eur J Pain"},{"issue":"5","key":"836_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/j.1532-2149.2013.00415.x","volume":"18","author":"CG Maihofner","year":"2014","unstructured":"Maihofner CG, Heskamp ML. Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study. Eur J Pain. 2014;18(5):671\u20139.","journal-title":"Eur J Pain"},{"key":"836_CR20","unstructured":"European Medicines Agency. Qutenza Product Information. Annex 1: Summary of product characteristics. 2015. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000909\/WC500040453.pdf ."},{"issue":"2","key":"836_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young Jr JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149\u201358.","journal-title":"Pain"},{"issue":"5","key":"836_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"issue":"11","key":"836_CR23","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"issue":"1","key":"836_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","volume":"27","author":"H Hurst","year":"2004","unstructured":"Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27(1):26\u201335.","journal-title":"J Manipulative Physiol Ther"},{"issue":"11","key":"836_CR25","first-page":"1","volume":"21","author":"MD Grant","year":"2006","unstructured":"Grant MD, Samson D. Special report: measuring and reporting pain outcomes in randomized controlled trials. Technol Eval Cent Assess Program Exec Summ. 2006;21(11):1\u20132.","journal-title":"Technol Eval Cent Assess Program Exec Summ"},{"issue":"6","key":"836_CR26","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","volume":"14","author":"SJ Walters","year":"2005","unstructured":"Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523\u201332.","journal-title":"Qual Life Res"},{"issue":"6","key":"836_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/11589370-000000000-00000","volume":"31","author":"E Anastassiou","year":"2011","unstructured":"Anastassiou E, Iatrou CA, Vlaikidis N, Vafiadou M, Stamatiou G, Plesia E, et al. Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. Clin Drug Investig. 2011;31(6):417\u201326.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"836_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/AJP.0000000000000082","volume":"31","author":"HG Markley","year":"2015","unstructured":"Markley HG, Dunteman ED, Kareht S, Sweeney M. Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN). Clin J Pain. 2015;31(1):58\u201365.","journal-title":"Clin J Pain"},{"issue":"1","key":"836_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jpain.2016.09.008","volume":"18","author":"DM Simpson","year":"2017","unstructured":"Simpson DM, Robinson-Papp J, Van J, Stoker M, Jacobs H, Snijder RJ, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42\u201353.","journal-title":"J Pain"},{"key":"836_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12883-016-0752-7","volume":"16","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Perrot S, Vinik EJ, Pazdera L, Jacobs H, Stoker M, Long SK, Snijder RJ, van der Stoep M, Ortega E, Katz N. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16:251.","journal-title":"BMC Neurol"},{"key":"836_CR31","doi-asserted-by":"crossref","unstructured":"Simpson DM, Brown S, Tobias JK, Vanhove GF, the NGX-4010 C107 Study Group. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study. Clin J Pain. 2014;30(2):134\u201342.","DOI":"10.1097\/AJP.0b013e318287a32f"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-017-0836-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T19:33:04Z","timestamp":1658950384000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-017-0836-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1186\/s12883-017-0836-z","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,21]]},"article-number":"80"}}